Session Details

[28-28-pm]Chemical biology 3

Sat. Mar 28, 2026 1:10 PM - 3:10 PM JST
Sat. Mar 28, 2026 4:10 AM - 6:10 AM UTC
Room 28 (3201, Bldg. 3, Area 4 [2F])
Chair: Naoya Ieda, Hiroyuki Yamakoshi

[28-28-pm01S]Studies toward Activity Improvement of the Catalyst for Intracellular Lysine Acylation

○Yuto Azumaya1, Yuki Yamanashi1, Motomu Kanai1 (1. Grad. Sch. Pharm. Sci., The Univ. of Tokyo)

[28-28-pm02S]Elucidation of nucleosome-binding proteins interactions using nucleosome covalent binding ligand

○Mayo Yamazaki1, Tamiko Nozaki1, Ayaka Nakashima1, Yuta Otobe2, Hikari Yoshitane2, Motomu Kanai1, Shigehiro Kawashima1 (1. Grad. Sch. Pharm. Sci., The Univ. of Tokyo, 2. TMIMS)

[28-28-pm03]Development of proteolysis targeting chimeras using an E3 ligase, CHIP.

○Tokiha Masuda-Ozawa1, Shusuke Tomoshige1, Eisuke Hayakawa1, Shinich Sato1,2, Kenji Ohgane3, Fumiaki Ohtake4, Minoru Ishikawa1 (1. Grad. Sch. Life Sci. Tohoku Univ., 2. FRIS Tohoku Univ., 3. Dept. Chem. Ochanomizu Univ., 4. Inst. Adv. Life Sci. Hoshi Univ.)

[28-28-pm04S]Development of a Visible-Light-Induced Caging Method Based on sp² Carbon–Boron Bond Cleavage

○Masaki Sano1, Sho Murakami2, Yuto Sumida3, Hirohisa Ohmiya2 (1. Graduate School of Pharmaceutical Sciences, Kyoto University, 2. Graduate School of Engineering, Kyoto University, 3. Laboratory for Biomaterials and Bioengineering, IIR, Institute of Science Tokyo)

[28-28-pm05S]Development of novel covalent drugs utilizing the warhead reactivity control by cancer specific enzymes

○Tadashi Imoto1, Kyohhei Fujita2, Takuya Hashimoto3, Yasuteru Urano1,2 (1. Grad. Sch. Pharm. Sci., The University of Tokyo, 2. Grad. Sch. Med. Sci., The University of Tokyo, 3. Pioneering Research Institute, RIKEN)

[28-28-pm06S]Development of selective inhibitors for a reactive sulfur species (RSS)-producing enzyme, cystathionine β-synthase (CBS)

○Ko Hirabayashi1, Hisashi Ohno1, Tomio Iwasaki2, Takashi Isobe3, Daisuke Aoki3, Orie Takayama1, Eita Sasaki1, Kenjiro Hanaoka1 (1. Grad. Sch. Pharm. Sci., Keio Univ., 2. Hitachi, Ltd., 3. Hitachi High-Tech Corp.)

[28-28-pm07S]In vivo pharmacokinetics and therapeutic efficacy of silicon phthalocyanine derivatives for near-infrared photoimmunotherapy

○Daiki Hara1, Hideo Takakura1, Syuhei Okuyama1,2, Naoya Kondo1, Hisataka Kobayashi1,3 (1. NIR-PIT Res. Inst., Kansai Med. Univ., 2. Shimadzu Corporation, 3. Molecular Imaging Branch, National Cancer Institute)

[28-28-pm08]FLG249 exhibits FXR antagonist activity by inducing dissociation of both corepressors and coactivators from FXR

○Yusuke Iguchi1, Yukiko Yamashita1, Keigo Gohda2, Ko Fujimori3, Naoki Teno4 (1. Fac. Pharm. Sci., Hiroshima Int. Univ., 2. CAMM-Kansai, 3. Fac. Pharm., Osaka Med. Pharm. Univ., 4. Fac. Clin. Nut., Hiroshima Int. Univ.)

[28-28-pm09S]Multicolor Raman imaging by 10th core atom-substituted 9CN-pyronin derivatives

○Shunsuke Kanai1, Hiroyoshi Fujioka2, Yasuyuki Ozeki3, Mako Kamiya2 (1. Department of Life Science and Technology, Institute of Science Tokyo, 2. Laboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, 3. Research Center for Advanced Science and Technology, The University of Tokyo)

[28-28-pm10S]Development of an activatable fluorescent probe for enzyme activity with improved cellular retention using phosphonate moiety

○Aoi Ishikawa1, Hiroyoshi Fujioka2, Mako Kamiya2 (1. Department of Life Science and Technology, Institute of Science Tokyo, 2. Laboratory for Chemistry and Life Science, Institute of Science Tokyo)